Lu Wang, MD, PhD, MS

CIO 2023-13 IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab vs surveillance in hepatocellular carcinoma patients

Purpose: The risk of HCC recurrence after liver resection or ablation with curative intent is 70-80% within 5 years, indicating an unmet need for effective adjuvant therapies. Atezolizuma...

Jeong Heo , MD, PhD;

David Hsieh , MD;

Masatoshi Kudo , MD, PhD;

Han Chu Lee , MD, PhD;

Qinshu Lian , PhD;

Shinichiro Nakamura , MD, PhD;

Kazushi Numata , MD;

Shukui Qin , MD, PhD;

Jessica Spahn , PhD;

Won Young Tak , MD, PhD;

Thomas Uguen , MD;

Edward Cha , PhD;

Lu Wang , MD, PhD, MS;

Minshan Chen , MD, PhD;

Xiaoyu Wen , MD, PhD;

Ann-Lii Cheng , MD, PhD;

Chun Wu , PharmD;

Pierce Chow , MBBS, FRCS, PhD;

Adam Yopp , MD;

Stephen Hack , MBChB;

Jian Zhou , MD, PhD;

11/01/2023

Original Contribution

Radiation Reduction in the Pediatric Catheterization Laboratory Using a Novel Imaging System

10/15/2017

Stephen Manu , MD;

Patcharapong Suntharos , MD;

Gerard J. Boyle , MD;

Lourdes R. Prieto , MD;

Lu Wang , MD, PhD, MS;

Radiation dose was compared between two modern imaging systems with different x-ray tube technology (Megalix vs Gigalix) and detector type (amorphous vs crystalline silicon) at the same institution in pediatric patients.

Radiation dose was compared...

10/15/2017

Journal of Invasive Cardiology